RETACRIT

Manufacturer:

Vifor

Name:

RETACRIT

HCPCS Code Descriptor:

Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units

Category:

Q Code

HCPCS:

Q5105

NDC(s):

59353-0010-01, 59353-0004-01, 59353-0002-01, 59353-0003-01, 59353-0220-10, 59353-0220-01, 59353-0010-10, 59353-0120-01, 59353-0120-10, 59353-0004-10, 59353-0003-10, 59353-0002-10, 00069-1318-10, 00069-1311-10, 00069-1309-04, 00069-1308-10, 00069-1307-10, 00069-1306-10, 00069-1305-10

Primary Type:

Oncology Biosimilar Colony Stimulating Factor

Generic Status:

Multi-Source

Route of Administration:

Subcutaneous

About:

RETACRIT is an Oncology Biosimilar Colony Stimulating Factor drug manufactured by Vifor and administered via the Subcutaneous route of administration. The Q Code: Q5105 is aligned to the drug RETACRIT.

Retacrit (epoetin) is an artificial protein that aids the production of red blood cells in the body. This medication is used to help with the side effects of certain medications, blood disorders, and kidney disorders. Retacrit is produced by Pfizer and Vifor and is biosimilar to the medications Epogen (J0885) and Procrit (J0885). This medication has two Q Codes: Q5105 for esrd use and Q5106 for non-esrd use. Both these Q codes became effective in January 2020 and still are aligned to the medication. Patient assistance programs can be found through Pfizer Oncology Together and Pfizer RxPathways.